NCT03779230View on ClinicalTrials.gov

Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

May 31, 2019

Primary Completion Date

June 27, 2023

Study Completion Date

June 27, 2023

Conditions
Glioma of Brain
Interventions
DRUG

L19TNF

Patients will be assigned to the following increasing dose levels of L19TNF: 10 and 13 μg/kg.

Trial Locations (3)

3010

Inselspital Bern, Bern

CH-1011

CHUV Départment d'Oncologie, Lausanne

CH-8091

Universitatspital Zurich - Klinik fur Neurologie & Hirntumorzentrum, Zurich

All Listed Sponsors
lead

Philogen S.p.A.

INDUSTRY

NCT03779230 - Safety and Efficacy of L19TNF in Patients With Isocitrate Dehydrogenase (IDH) Wildtype WHO Grade III / IV Glioma at First Relapse | Biotech Hunter | Biotech Hunter